



**ASX ANNOUNCEMENT**

1 October 2019

**Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth)**

Probiotec Limited (ASX: PBP) ("**Probiotec**" or the "**Company**") has today issued 6,000,000 new fully paid ordinary shares in the Company ("**New Shares**") to institutional, sophisticated and professional investors, at an issue price of A\$1.76 per New Share. The New Shares have been issued as a result of the Placement detailed in the announcement to ASX on 25 September 2019.

Probiotec gives notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**) that:

- 1 the New Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- 2 this notice is being given under section 708A(5)(e) of the Corporations Act;
- 3 as at the date of this notice, the Company has complied with:
  - (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - (b) section 674 of the Corporations Act; and
- 4 as at the date of this notice, there is no information that is "excluded information" of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act that is required to be disclosed by the Company under section 708A(6)(e) of the Corporations Act.

For and on behalf of the board

**Jared Stringer**  
**Company Secretary**

**About Probiotec**

Probiotec Limited is a manufacturer, packer and distributor of a range of prescription and over-the-counter (OTC) pharmaceuticals, complementary medicines and consumer health products. The company owns three manufacturing facilities across Australia. Products are manufactured by Probiotec on behalf of a range of clients, including major international pharmaceutical companies.

Further details about Probiotec are available at [www.probiotec.com.au](http://www.probiotec.com.au)

For further information contact:

Wes Stringer, Managing Director

Ph: (03) 9278 7555